Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has expanded a contract manufacturing agreement originally disclosed in March 2026, increasing the value from KRW 350.0B to KRW 400.7B upon the client’s request.
📊 [Key Disclosure Details & Financial Summary]
- Original Disclosure Date: 2026-03-13
- Amendment Date: 2026-06-09
- Reason for Amendment: Contract value adjustment requested by the client
- Comparison of Key Contract Terms:
- Contract Value:
- Before Amendment: KRW 349,972,700,000 (USD 236,500,000)
- After Amendment: KRW 400,715,042,000 (USD 270,790,000, Increased by USD 34,290,000)
- Ratio to Revenue:
- Before Amendment: 7.70% (Based on FY2024 consolidated revenue of KRW 4,547,322,176,421)
- After Amendment: 8.81% (Based on FY2024 consolidated revenue of KRW 4,547,322,176,421)
- Contract Value:
- Other Key Contract Details:
- Contract Name: Contract Manufacturing Agreement for Pharmaceuticals
- Counterparty: Europe-based Pharmaceutical Company (Undisclosed until March 13, 2032, due to trade secret protection)
- Contract Period: 2025-07-31 ~ 2032-03-13 (End date subject to change upon mutual agreement)
- Execution Date: 2025-08-11
- Non-disclosure Period: 2032-03-13 (Due to business confidentiality)
- Applied Exchange Rate: Applied initial FX rate of USD/KRW 1,479.80 as of March 13, 2026
- Contract Background: Originally executed in August 2025 below disclosure threshold, but disclosed on March 13, 2026, upon fulfillment of conditions that finalized the minimum order quantity
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Future Amended Disclosures Regarding Changes in Contract Value or End Date
This filing is a correction disclosure regarding an increase in the contract value of a previously executed manufacturing agreement. Verifying whether further adjustments to the contract value or end date occur through mutual agreement is important for identifying any subsequent changes to the finalized contract terms. Relevant updates can be verified in future amended disclosures and upcoming periodic reports.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
